Jump to content

Fasiplon

From Wikipedia, the free encyclopedia
Fasiplon
Clinical data
ATC code
  • none
Identifiers
  • 6-Ethyl-7-methoxy-5-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyrimidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H15N5O2
Molar mass273.296 g·mol−1
3D model (JSmol)
  • CC1=NC(C2=CN3C(N=C(OC)C(CC)=C3C)=N2)=NO1
  • InChI=1S/C13H15N5O2/c1-5-9-7(2)18-6-10(11-14-8(3)20-17-11)15-13(18)16-12(9)19-4/h6H,5H2,1-4H3 ☒N
  • Key:MEBYKPLMXIRYRQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fasiplon (RU 33203) is a nonbenzodiazepine anxiolytic drug from the imidazopyrimidine family of drugs.

Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action.[1] It was developed by a team at Roussel Uclaf in the 1990s[2]

References

[edit]
  1. ^ Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry. 34 (7): 2060–7. doi:10.1021/jm00111a021. PMID 1648620.
  2. ^ US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fasiplon&oldid=1135227643"